多组学分析阐明了乳腺癌肿瘤内微生物组与宿主免疫异质性之间的关系。
Multi-omics analysis elucidates the relationship between intratumor microbiome and host immune heterogeneity in breast cancer.
机构信息
Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
出版信息
Microbiol Spectr. 2024 Apr 2;12(4):e0410423. doi: 10.1128/spectrum.04104-23. Epub 2024 Mar 5.
Research has indicated that intratumor microbiomes affect the occurrence, progression, and therapeutic response in many cancer types by influencing the immune system. We aim to evaluate the characteristics of immune-related intratumor microbiomes (IRIMs) in breast cancer (BC) and search for potential prognosis prediction factors and treatment targets. The clinical information, microbiome data, transcriptomics data of The Cancer Genome Atlas Breast Invasive Carcinoma (TCGA-BRCA) patients were obtained from Kraken-TCGA-Raw-Data and TCGA portal. The core tumor-infiltrating immune cell was identified using univariate Cox regression analysis. Based on consensus clustering analysis, BC patients were categorized into two immune subtypes, referred to as immune-enriched and immune-deficient subtypes. The immune-enriched subtype, characterized by higher levels of immune infiltration of CD8+ T and macrophage M1 cells, demonstrated a more favorable prognosis. Furthermore, significant differences in alpha-diversity and beta-diversity were observed between the two immune subtypes, and the least discriminant analysis effect size method identified 33 types of IRIMs. An intratumor microbiome-based prognostic signature consisting of four prognostic IRIMs (, , , and ) was constructed using the Cox proportional-hazard model, and it had great prognostic value. The prognostic IRIMs were correlated with immune gene expression and the sensitivity of chemotherapy drugs, specifically tamoxifen and docetaxel. In conclusion, our research has successfully identified two distinct immune subtypes in BC, which exhibit contrasting prognoses and possess unique epigenetic and intratumor microbiomes. The critical IRIMs were correlated with prognosis, tumor-infiltrating immune cell abundance, and immunotherapeutic efficacy in BC. Consequently, this study has identified potential IRIMs as biomarkers, providing a novel therapeutic approach for treating BC.IMPORTANCERecent research has substantiated the presence of the intratumor microbiome in tumor immune microenvironment, which could influence tumor occurrence and progression, as well as provide new opportunities for cancer diagnosis and treatment. This study identified the critical immune-related intratumor microbiome (, , , and ), which were correlated with prognosis, tumor-infiltrating immune cell abundance, and immunotherapeutic efficacy in breast cancer and might be the novel target to regulate immunotherapy in BC.
研究表明,肿瘤内微生物组通过影响免疫系统,影响许多癌症类型的发生、进展和治疗反应。我们旨在评估乳腺癌(BC)中免疫相关肿瘤内微生物组(IRIM)的特征,并寻找潜在的预后预测因素和治疗靶点。从 Kraken-TCGA-Raw-Data 和 TCGA 门户获取了 TCGA-BRCA 患者的临床信息、微生物组数据和转录组学数据。使用单变量 Cox 回归分析鉴定核心肿瘤浸润免疫细胞。基于共识聚类分析,将 BC 患者分为两种免疫亚型,称为免疫富集和免疫缺陷亚型。免疫富集亚型的特点是 CD8+T 和巨噬细胞 M1 细胞的免疫浸润水平更高,预后更好。此外,两种免疫亚型之间观察到 alpha 多样性和 beta 多样性存在显著差异,最小判别分析效应大小方法鉴定了 33 种 IRIM 类型。使用 Cox 比例风险模型构建了一个基于肿瘤内微生物组的预后标志,由四个预后 IRIM(,,,和)组成,具有很好的预后价值。预后 IRIM 与免疫基因表达和化疗药物(特别是他莫昔芬和多西紫杉醇)的敏感性相关。总之,我们的研究成功地在 BC 中鉴定了两种不同的免疫亚型,它们表现出相反的预后,并具有独特的表观遗传和肿瘤内微生物组。关键的 IRIM 与 BC 的预后、肿瘤浸润免疫细胞丰度和免疫治疗疗效相关。因此,这项研究确定了潜在的 IRIM 作为生物标志物,为治疗 BC 提供了一种新的治疗方法。
重要性
最近的研究证实了肿瘤免疫微环境中存在肿瘤内微生物组,这可能影响肿瘤的发生和发展,并为癌症的诊断和治疗提供新的机会。本研究鉴定了关键的免疫相关肿瘤内微生物组(,,,和),它们与乳腺癌的预后、肿瘤浸润免疫细胞丰度和免疫治疗疗效相关,可能是调节 BC 免疫治疗的新靶点。